Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Remdesivir for the Treatment of Covid-19 - Final Report

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dapagliflozin in Patients with Chronic Kidney Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genome-wide association study of high-sensitivity C-reactive protein, D-dimer and Interleukin-6 levels in multi-ethnic HIV+ cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  • John H Beigel
  • Kay M Tomashek
  • Lori E Dodd
  • Aneesh K Mehta
  • Barry S Zingman
  • Andre C Kalil
  • Elizabeth Hohmann
  • Helen Y Chu
  • Annie Luetkemeyer
  • Susan Kline
  • Diego Lopez de Castilla
  • Robert W Finberg
  • Kerry Dierberg
  • Victor Tapson
  • Lanny Hsieh
  • Thomas F Patterson
  • Roger Paredes
  • Daniel A Sweeney
  • William R Short
  • Giota Touloumi
  • David Chien Lye
  • Norio Ohmagari
  • Myoung-Don Oh
  • Guillermo M Ruiz-Palacios
  • Thomas Benfield
  • Gerd Fätkenheuer
  • Mark G Kortepeter
  • Robert L Atmar
  • C Buddy Creech
  • Jens Lundgren
  • Abdel G Babiker
  • Sarah Pett
  • James D Neaton
  • Timothy H Burgess
  • Tyler Bonnett
  • Michelle Green
  • Mat Makowski
  • Anu Osinusi
  • Seema Nayak
  • H Clifford Lane
  • ACTT-1 Study Group Members
  • Birgitte Lindegaard Madsen (Member of study group)
  • Tomas Østergaard Jensen (Member of study group)
View graph of relations

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.

METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.

RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).

CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).

Original languageEnglish
JournalThe New England journal of medicine
Volume383
Issue number19
Pages (from-to)1813-1826
Number of pages14
ISSN0028-4793
DOIs
Publication statusPublished - 5 Nov 2020

ID: 59909544